Losartan Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Source (Contract Manufacturing Organizations, In-House), By Application (Hypertension, Stroke, Diabetic Nephropathy, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 743.21 Million
CAGR (2026-2031)	3.87%
Fastest Growing Segment	Contract Manufacturing Organizations
Largest Market	North America
Market Size (2031)	USD 933.37 Million

Market Overview

The Global Losartan Market is projected to grow from USD 743.21 Million in 2025 to USD 933.37 Million by 2031 at a 3.87% CAGR. Losartan, an angiotensin II receptor blocker (ARB), is a pharmaceutical product primarily prescribed for managing hypertension, also known as high blood pressure, and related cardiovascular conditions such as diabetic nephropathy. The market's growth is largely supported by the increasing global prevalence of hypertension and an expanding aging population, both contributing to a larger patient demographic requiring consistent pharmacological treatment. According to the World Health Organization, in its 2025 Global Hypertension Report, approximately 1.4 billion people lived with hypertension in 2024, underscoring a substantial and growing demand for effective antihypertensive therapies. Heightened awareness of early diagnosis and the long-term management of hypertension further propels market expansion.

A considerable challenge impacting market growth involves the intense generic competition and ongoing pricing pressures. As a widely available generic medication, Losartan consistently contends with other ARBs and alternative classes of antihypertensive drugs. This competitive environment, combined with global healthcare cost containment strategies, exerts downward pressure on pharmaceutical pricing and consequently limits the potential for revenue expansion.

Key Market Drivers

The increasing global prevalence of hypertension stands as a primary driving force for the Global Losartan Market, directly expanding the patient pool requiring effective antihypertensive treatments. Hypertension continues to impact a significant portion of the adult population worldwide, necessitating sustained pharmacological interventions such as Losartan. According to the World Health Organization, in its 2025 Global Hypertension Report released on September 23, 2025, over 10 million lives are claimed every year by uncontrolled high blood pressure, demonstrating a consistently high demand for accessible and proven medications. This pervasive health challenge fuels consistent prescription rates and underscores the critical role Losartan plays in mitigating cardiovascular risks.

Concurrently, the growing geriatric population demographics globally significantly contribute to the expansion of the Losartan market. Older individuals are inherently more susceptible to developing hypertension and other cardiovascular diseases, leading to an increased need for chronic medication management. According to the World Health Organization on October 1, 2025, the global population aged 60 and above is expected to increase from 1.1 billion in 2023 to 1.4 billion by 2030, presenting a larger demographic requiring long-term treatment solutions. This demographic shift translates directly into a broader patient base for Losartan, given its established efficacy and widespread availability. Moreover, the extensive availability of generic Losartan formulations enhances market accessibility and affordability. According to the Association for Accessible Medicines and the Biosimilars Council, in their 2025 U.S. Generic & Biosimilar Medicines Savings Report released on September 3, 2025, generic and biosimilar medicines generated $467 billion in savings for patients and the U.S. healthcare system in 2024, highlighting the economic benefit and wider adoption of such medications.

Download Free Sample Report

Key Market Challenges

The global Losartan market faces significant challenges from intense generic competition and ongoing pricing pressures. As a widely available generic angiotensin II receptor blocker, Losartan constantly competes with numerous other generic antihypertensive drugs, including other ARBs and different therapeutic classes. This highly competitive environment, coupled with pervasive healthcare cost containment strategies worldwide, exerts considerable downward pressure on pharmaceutical pricing. This directly limits the revenue expansion potential for manufacturers of Losartan.

The financial impact of such competition is substantial across the generic pharmaceutical sector. According to the Association for Accessible Medicines (AAM), in its 2025 U.S. Generic & Biosimilar Medicines Savings Report, generic and biosimilar medicines constituted 90 percent of all prescriptions filled in 2024, yet they accounted for merely 12 percent of the total prescription spending. This disparity underscores the profound pricing pressures within the generic segment, which directly translates to constrained profitability and stifled growth for individual generic products like Losartan. The consistent drive for lower-cost alternatives diminishes the per-unit revenue, thereby restricting the overall market value despite high prescription volumes.

Key Market Trends

The development of novel drug formulations represents a significant trend influencing the Global Losartan Market, enhancing accessibility and patient adherence. These innovations address specific patient needs, particularly for individuals who face challenges with traditional solid oral dosage forms. For example, the introduction of ready-to-use liquid formulations of Losartan streamlines administration for pediatric and geriatric populations or those with dysphagia, removing the complexities and inconsistencies associated with compounded medications. According to Scienture Holdings, Inc.'s commercial update on February 03, 2026, the company has expanded U.S. access for Arbli™, the first FDA-approved ready-to-use oral liquid formulation of losartan, to more than 2,500 healthcare institutions nationwide through Institutional GPO agreements, demonstrating a concerted effort to broaden market reach and improve patient care.

Another prominent trend is the expanding clinical applications for Losartan beyond its primary indication of hypertension. While Losartan is well-established for blood pressure management, ongoing research and evolving clinical guidelines increasingly underscore its utility in other cardiovascular and renal conditions, such as heart failure and diabetic nephropathy. This broadened therapeutic scope positions Losartan as a versatile agent, offering multifaceted benefits that extend to critical organ protection and improved patient outcomes in various complex health scenarios. According to a study published on September 04, 2025, in the American Heart Association Journals' "Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers: Multidatabase Target Trial Emulation Studies", the 5-year cumulative incidence of all-cause mortality among patients initiating ARBs was 3.04%, notably lower than the 3.45% for those initiating ACE inhibitors, reinforcing the strong protective efficacy of ARBs in a broader clinical context.

Segmental Insights

The Contract Manufacturing Organizations (CMOs) segment is experiencing rapid growth within the Global Losartan Market, emerging as the fastest-growing category. This surge is primarily driven by pharmaceutical companies' increasing demand for operational efficiency and cost optimization in the production of established generic drugs like Losartan. By leveraging CMOs, companies avoid significant capital investments in manufacturing infrastructure and benefit from economies of scale, specialized expertise, and advanced production technologies. Furthermore, CMOs offer crucial flexibility and scalability to meet fluctuating market demands, while also ensuring stringent adherence to global regulatory requirements, including Good Manufacturing Practices (GMP) set by authorities such as the FDA, thereby mitigating compliance risks. This strategic outsourcing allows pharmaceutical firms to concentrate their resources on core competencies like research and development.

Regional Insights

North America dominates the global Losartan market primarily due to the substantial prevalence of hypertension and cardiovascular diseases within the region, driving significant demand for effective antihypertensive treatments. This market leadership is reinforced by a highly developed healthcare infrastructure, which features advanced medical facilities and a strong emphasis on research and development. Furthermore, the presence of leading pharmaceutical companies actively engaged in the development and commercialization of Losartan contributes significantly. Favorable reimbursement policies and robust regulatory frameworks, including stringent oversight from the U.S. Food and Drug Administration, ensure market stability and patient access, collectively solidifying North America's prominent position.

Recent Developments

• In December 2025, Scienture Holdings Inc. announced a strategic collaboration with BlinkRx to enhance nationwide access to Arbli™, its newly approved oral liquid formulation of losartan potassium. This company collaboration aimed to make Arbli™, the first FDA-approved ready-to-use oral suspension of losartan, available through the BlinkRx patient access platform starting in the first quarter of 2026. The partnership was designed to streamline the prescription journey, reduce administrative delays, improve therapy initiation, and support long-term adherence for patients requiring liquid medication options in the Losartan market.
• In October 2025, Scienture Holdings Inc. achieved a key milestone with the commercial availability of Arbli™ (losartan potassium) Oral Suspension, 10mg/mL, through full-line wholesalers nationwide. This new product launch into established pharmaceutical distribution channels ensured that the first FDA-approved ready-to-use liquid losartan formulation was accessible across the United States. It significantly addressed the unmet needs of underserved patients, including elderly individuals and children as young as six, who experience dysphagia and previously relied on inconsistent compounded formulations for their losartan medication.
• In September 2025, Graviti Pharms initiated the marketing of its generic Losartan Potassium tablets, marking a new product launch in the global Losartan market. The company introduced its Losartan Potassium tablets in multiple strengths, including 25mg, 50mg, and 100mg, which expanded the range of available and affordable treatment options for patients. This development contributes to the increasing competition within the generic segment of the Losartan market, providing healthcare providers and patients with additional choices for managing hypertension and associated conditions effectively.
• In March 2025, Scienture Holdings Inc. announced U.S. Food and Drug Administration (FDA) approval of Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL. This marked a significant new product launch in the global Losartan market as Arbli™ became the first FDA-approved, ready-to-use oral liquid formulation of losartan in the United States. It is indicated for treating hypertension in patients older than six years, reducing stroke risk in individuals with hypertension and left ventricular hypertrophy, and managing diabetic nephropathy in certain type 2 diabetes patients. This innovation provides a crucial alternative for patients who require or prefer liquid medications, eliminating the need for extemporaneous compounding.

Key Market Players

• Merck & Co. Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Novartis International AG
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceuticals Industries Ltd.
• Aurobindo Pharma Ltd.
• Torrent Pharmaceutical Ltd.
• Lupin Ltd.

By Source	By Application	By Region
Contract Manufacturing Organizations In-House	Hypertension Stroke Diabetic Nephropathy Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Losartan Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Losartan Market, By Source:

• Contract Manufacturing Organizations
• In-House

• Losartan Market, By Application:

• Hypertension
• Stroke
• Diabetic Nephropathy
• Others

• Losartan Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE